HOUSTON & MUNICH--(BUSINESS WIRE)--InGeneron, Inc., a regenerative medicine and biotechnology company, announced today that Angelo Moesslang, PhD, former Chief Financial Officer (CFO) of Fresenius Medical Care North America, has joined InGeneron and will serve as the new Chief Executive Officer (CEO).
Angelo Moesslang brings over 20 years of leadership experience and a proven track record as a finance and healthcare executive in the medical device industry. He will closely work together with Ron Stubbers, MBA, who will continue leading the company’s operational activities.
“I am delighted to join this stellar team at such an exciting time for the company,” said Angelo Moesslang, PhD, Chief Executive Officer of InGeneron. “InGeneron’s technology has immense clinical and commercial potential and the company is executing a well-defined and promising clinical program with two FDA clinical trials already underway. I look forward to working with the team on their mission to establish the therapeutic benefit of the approach and bring regenerative cell therapy into clinical practice.”
“With his valuable expertise in the medical device industry, his understanding of the US and European healthcare systems as well as his experience in negotiating strategic partnerships and entering markets overseas, Angelo is a perfect fit for guiding InGeneron through the next stage of development,” said Eckhard Alt, MD, PhD, Chairman of the Board of InGeneron. “He is an excellent addition to the company and will help us to further establish a leading position in the field of regenerative medicine. We are very pleased to welcome him to the team.”
Prior to joining InGeneron, Angelo Moesslang was CFO of Fresenius Medical Care North America Holdings, Inc., the US-based division of Fresenius Medical Care, a global medical device and healthcare services group. Earlier roles in his career include CFO for Fresenius Medical Care Europe, Africa, Middle East & Latin America, Vice President for Business Development for Fresenius Medical Care Asia Pacific, and Head of Investor Relations for Fresenius Medical Care. Angelo Moesslang holds a Doctorate in Business Administration from the University of Hohenheim and a Master’s Degree in Economics from the Ludwig-Maximilian University of Munich.
InGeneron is elevating the field of regenerative medicine by translating robust science into proven patient benefit. Our purpose is to set new therapeutic standards by enabling physicians to use the patients’ own regenerative cells at point of care. With the initial focus on key orthopedic and wound healing indications, we will make regenerative cell therapies broadly accessible across multiple medical fields. www.ingeneron.com